Fig. 1
Long-term efficacy of LCAR-B38M. A) The column graph shows the number of patients with different survival states. CR: complete response; PD: progressive disease. (B, C) The Kaplan-Meier survival curves show the progression-free survival (PFS) rate (B) and the overall survival (OS) rate (C) of all 74 patients at a median follow-up time of 65.4 months. (D, E) The Kaplan-Meier survival curves compare the PFS (D) and OS (E) rates between the 54 patients achieving CR and the rest who did not have CR (Non-CR). (F, G) The Kaplan-Meier survival curves compare the PFS (F) and OS (G) rates between the two CR cohorts with (Non-MRDneg CR) and without (MRDneg CR) measurable residual disease (MRD), respectively